1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: Active drug monitoring to assess the impact of immune response on drug exposure
    Journal Article

    Spreafico, A.; Couselo, E. M.; Irmisch, A.; Bessa, J.; Au-Yeung, G.; Bechter, O.; Svane, I. M.; Sanmamed, M. F.; Gambardella, V.; McKean, M.; more...
    Frontiers in Oncology (2024)

    Fulltext@MSK | Save
  • Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis
    Journal Article

    Piulats, J. M.; Watkins, C.; Costa-García, M.; del Carpio, L.; Piperno-Neumann, S.; Rutkowski, P.; Hassel, J. C.; Espinosa, E.; de la Cruz-Merino, L.; Ochsenreither, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Clearance of plasma cell free DNA in metastatic uveal melanoma with radiographic response to immune checkpoint inhibitors
    Journal Article

    Francis, J. H.; Barker, C. A.; Canestraro, J.; Abramson, D. H.; Shoushtari, A. N.
    American Journal of Ophthalmology Case Reports (2024)

    Fulltext@MSK | Save
  • Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)
    Journal Article

    Callahan, M.; Amin, A.; Kaye, F. J.; Morse, M. A.; Taylor, M. H.; Peltola, K. J.; Sharma, P.; O'Reilly, E. M.; Meadows Shropshire, S.; O'Brien, S.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: A systematic review and meta-analysis
    Review

    Sala, I.; Pagan, E.; Pala, L.; Oriecuia, C.; Musca, M.; Specchia, C.; De Pas, T.; Cortes, J.; Giaccone, G.; Postow, M.; more...
    Frontiers in Immunology (2024)

    Fulltext@MSK | Save
  • Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
    Journal Article

    Memon, D.; Schoenfeld, A. J.; Ye, D.; Fromm, G.; Rizvi, H.; Zhang, X.; Keddar, M. R.; Mathew, D.; Yoo, K. J.; Qiu, J.; more...
    Cancer Cell (2024)

    Fulltext@MSK | Save
  • Prevalence of enteric infections in patients on immune checkpoint inhibitors and impact on management and outcomes
    Journal Article

    Magahis, P. T.; Satish, D.; Babady, N. E.; Kamboj, M.; Postow, M. A.; Laszkowska, M.; Faleck, D. M.
    The Oncologist (2024)

    Fulltext@MSK | Save
  • The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
    Journal Article

    Hepner, A.; Versluis, J. M.; Wallace, R.; Allayous, C.; Brown, L. J.; Trojaniello, C.; Gerard, C. L.; Jansen, Y. J. L.; Bhave, P.; Neyns, B.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitor therapy expands an activated, anti-PD-1 drug-bound CD8 T cell population that is clonally linked in blood and synovial fluid of ICI-arthritis patients
    Meeting Abstract

    Marks, K.; Singaraju, A.; Wang, R.; Adejoorin, I.; Fein, M.; Postow, M.; Chan, K. K.; Bass, A.; Donlin, L.; Rao, D.
    Arthritis & Rheumatology (2023)

    Fulltext@MSK | Save
  • Three-year overall survival with tebentafusp in metastatic uveal melanoma
    Journal Article

    Hassel, J. C.; Piperno-Neumann, S.; Rutkowski, P.; Baurain, J. F.; Schlaak, M.; Butler, M. O.; Sullivan, R. J.; Dummer, R.; Kirkwood, J. M.; Orloff, M.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save